Phase II Open-Label, Single-Center Study Evaluating Safety and Efficacy of Pembrolizumab Following Induction with the Hypomethylating Agent Azacitidine in Patients with Advanced Pancreatic Cancer After Failure of First-Line Therapy
Summary
The purpose of this phase II study is to determine the safety and effectiveness of combining immune therapy, pembrolizumab, with a hypomethylating agent, azacitidine, for pancreatic cancer.
General Information
NCT#: NCT03264404
Study ID: AAAR3554
Trial Phase: Phase II
Trial Sponsor: Columbia University
Therapies Used in This Trial: Azacitidine, Pembrolizumab